Compare Incyte Corporation (INCY) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VICI Properties Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while VICI Properties Inc trades at $26.83 (market cap $29.55B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays a 6.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VICI | |
|---|---|---|
Market Cap | $23.11B | $29.55B |
Sector | Health | Real Estate |
52-Week High | $118.52 | $33.93 |
52-Week Low | $67.38 | $25.94 |
Enterprise Value | $19.13B | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
VICI Properties trades at $26.83, down 0.15% on the day, with technical indicators showing a neutral bias. The REIT maintains strong fundamentals with a 76.83% net income margin and consistent earnings beats in three of the last four quarters. Recent news highlights institutional buying interest and dividend sustainability discussions amid sector volatility.
VICI offers a compelling value proposition with a 6.7% dividend yield and 36% upside to the consensus price target of $30.00. Key risks include tenant concentration with Caesars/MGM accounting for 70% of rent and macroeconomic sensitivity. Wall Street remains bullish with 77% buy ratings supporting long-term income growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
